Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Technology appraisal guidance
Reference number: TA779
Published:
Due to operational challenges the start of technical engagement will be delayed by a few days. We anticipate starting technical engagement week commencing 16 August 2021.